Scientists at Penn State College of Medicine have found that the gene EXO1, normally a DNA repair helper, can become harmful when produced in excess. Instead of fixing DNA, too much EXO1 causes damage that destabilizes genomes and is seen in multiple cancer types.
- EXO1 overexpressed in up to 30% of several cancers
- Excess EXO1 causes DNA breaks and genome instability
- Potential to guide personalized chemo targeting EXO1-high tumors
What happened
Researchers at Penn State examined the role of EXO1, a gene coding for a DNA repair protein, and found that when cells produce too much of it, the protein damages DNA instead of repairing it. Using tumor data and lab experiments, they showed that high EXO1 levels are common in breast, ovarian, melanoma, cervical, testicular, and hepatobiliary cancers. These cancers exhibit genome instability driven by EXO1’s excessive cutting of DNA.
By artificially increasing EXO1 in cancer cells, scientists observed that the protein cut DNA strands abnormally, creating harmful lesions such as double strand breaks. These breaks compromise genome stability and contribute to the aggressive behavior of tumors. Intriguingly, cancers with elevated EXO1 display characteristics similar to tumors with BRCA gene mutations, even when BRCA genes are normal.
Why it feels good
This insight overturns the traditional notion that more DNA repair is always beneficial, highlighting a nuanced balance essential for cellular health. Understanding how too much EXO1 activity harms DNA provides researchers a new perspective on cancer biology and the mechanisms behind genome destabilization.
Moreover, discovering the similarities between EXO1-overexpressing tumors and BRCA-mutant cancers creates optimism. It suggests these cancers could be treated similarly, using drugs already available for BRCA-related tumors but that might now help a wider group of patients without BRCA mutations.
What to enjoy or watch next
Future developments may see EXO1 levels used as biomarkers to tailor cancer therapy choices, advancing personalized medicine. Patients with tumors exhibiting high EXO1 could receive targeted chemotherapy known for effective BRCA-mutant cancers, potentially with fewer side effects.
Scientists will continue investigating the full spectrum of cancers affected by EXO1 overproduction and refine strategies to leverage this weakness. Watching for clinical trials testing these approaches could provide hopeful new options for many affected by aggressive and difficult-to-treat cancers.